Utility of a Dengue-Derived Monoclonal Antibody to Enhance Zika Infection In Vitro

Discussion
When determining the level of enhancement DENV2 strain 16803 achieved in the presence of 4G2, we found significant differences between titers from the treatment group with the antibody and the control group without the antibody (Table 1). In both the supernatant and pellet, the control group produced little or no plaques while the treatment group had countable plaques, which resulted in a mean value significant from the control group (p-values <0.05). Mean viral titers in the supernatant and pellet, respectively, increased more than 140-fold and 110-fold when pre-treated with antibody.

Table 1

Average DENV2 titers calculated based on n=10 replicates from plaque assays. Also reported is the 95% lower confidence limit (LCL) and upper confidence limit (UCL) in the control group (no antibody) and treatment group (with 4G2 antibody).

Virus
Location
Antibody
Mean
95% LCL
95% UCL

DENV2
Supernatant
Yes
1.27×103
1.03×103
1.51×103

DENV2
Supernatant
No
9
-1.14×101
2.9×101

DENV2
Pellet
Yes
1.10×102
2.44×102
1.96×102

DENV2
Pellet
No
...

Source: PLOS Currents Outbreaks - July 5, 2016 Category: Epidemiology Authors: acharl5 at lsu.edu Source Type: research